Table 3 Treatment of brain metastases from colorectal cancer
From: Prognostic factors of brain metastases from colorectal cancer
Initial treatment period | First half 1997–2005 | Second half 2006–2015 | p value |
|---|---|---|---|
Treatment of brain metastases | |||
WBRT or WBRT + SRT | 21 (58%) | 3 (9%) | 0.004 |
SRT | 4 (11%) | 13 (41%) | |
Surgery + SRT | 3 (8%) | 4 (13%) | |
Surgery or Surgery + WBRT | 4 (11%) | 9 (28%) | |
Supportive care | 4 (11%) | 3 (9%) | |
Regimen before diagnosis of brain metastases | |||
None | 13 (36%) | 9 (28%) | 0.011 |
Fluoropyrimidine only | 9 (25%) | 4 (13%) | |
Fluoropyrimidine + oxaliplatin | 2 (6%) | 4 (13%) | |
Fluoropyrimidine + irinotecan | 6 (17%) | 0 (0%) | |
Fluoropyrimidine + oxaliplatin + irinotecan | 6 (17%) | 15 (46%) | |
Targeted agents | |||
Not used | 34 (94%) | 11 (34%) | <.0001 |
Used | 2 (6%) | 21 (66%) | |